Medline (NASDAQ:MDLN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Medline (NASDAQ:MDLN) has been assigned an average recommendation of “Moderate Buy” from the twenty-nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $50.6154.

A number of analysts have commented on the company. Rothschild & Co Redburn set a $42.00 price target on Medline in a research report on Monday, January 12th. Mizuho started coverage on shares of Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price for the company. Zacks Research upgraded shares of Medline to a “hold” rating in a research note on Tuesday, January 13th. JPMorgan Chase & Co. upped their price target on shares of Medline from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 10th. Finally, UBS Group raised their price objective on shares of Medline from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, February 26th.

Institutional Trading of Medline

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Carlyle Group Inc. purchased a new stake in Medline during the 4th quarter valued at approximately $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new position in Medline during the fourth quarter valued at $4,179,591,000. Vanguard Group Inc. bought a new stake in Medline in the 4th quarter valued at $793,278,000. Morgan Stanley bought a new position in shares of Medline during the 4th quarter valued at about $636,807,000. Finally, Capital Research Global Investors purchased a new position in shares of Medline during the fourth quarter valued at about $620,937,000.

Medline Price Performance

Shares of MDLN stock opened at $41.36 on Friday. Medline has a 12 month low of $34.89 and a 12 month high of $50.88. The firm’s 50 day simple moving average is $44.75.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to analyst estimates of $7.52 billion. The business’s revenue was up 14.8% on a year-over-year basis.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.